methyl 2-hydroxy-4-(trityloxy)benzoate | 136669-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: methyl 2-hydroxy-4-(trityloxy)benzoate
• 英文别名: methyl 2-hydroxy-4-trityloxybenzoate
• CAS: 136669-90-4
• 化学式: C₂₇H₂₂O₄
• 分子量: 410.469
• InChiKey: YQCFUMFXEPULSH-UHFFFAOYSA-N

物化性质

• 沸点：
  560.4±45.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-hydroxy-4-(trityloxy)benzoate 在 Dowex 50x2 、 sodium hydride 作用下， 以 甲醇 为溶剂， 生成 4-羟基-2-甲基氧苯甲酸甲酯
  参考文献：
  名称：

  Safety-catch anchoring linkage for synthesis of peptide amides by Boc/Fmoc strategy

  摘要：

  2-Methoxy-4,4'-bis(methylthio)benzhydrylamine (10) and the corresponding disulfoxide were prepared and tested as a model amide protecting groups for their stability toward acidic conditions. Subsequently, the novel 4-[4,4'-bis(methylsulfinyl)-2-oxy-(9-fluorenylmethyloxycarbonyl) benzhydrylamino]butanoic acid (SCAL) handle (9) has been prepared and applied to solid-phase peptide synthesis of C-terminal peptide amide using both 9-fluorenylmethyloxycarbonyl (Fmoc) and tert-butyloxycarbonyl (Boc) groups for N-alpha-amino protection.

  DOI：

  10.1016/s0040-4039(00)79406-8
• 作为产物：
  描述：

  2,4-二羟基苯甲酸 在 4-二甲氨基吡啶 、 氯化亚砜 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-hydroxy-4-(trityloxy)benzoate
  参考文献：
  名称：

  Safety-catch anchoring linkage for synthesis of peptide amides by Boc/Fmoc strategy

  摘要：

  2-Methoxy-4,4'-bis(methylthio)benzhydrylamine (10) and the corresponding disulfoxide were prepared and tested as a model amide protecting groups for their stability toward acidic conditions. Subsequently, the novel 4-[4,4'-bis(methylsulfinyl)-2-oxy-(9-fluorenylmethyloxycarbonyl) benzhydrylamino]butanoic acid (SCAL) handle (9) has been prepared and applied to solid-phase peptide synthesis of C-terminal peptide amide using both 9-fluorenylmethyloxycarbonyl (Fmoc) and tert-butyloxycarbonyl (Boc) groups for N-alpha-amino protection.

  DOI：

  10.1016/s0040-4039(00)79406-8

文献信息

• [EN] NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES<br/>[FR] NOUVELLES SPIROPIPERIDINES OU SPIROPYRROLIDINES TRICYCLIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004005295A1

  公开（公告）日：2004-01-15

  The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）的化合物，其中m、R1、n、R2、q、X、Y、Z、R3、R4、R5、R6、R7、R8、t和R9如说明书所述，以及它们的制备过程、含有它们的药物组合物及其在治疗中的用途。
• Novel tricyclic spiropiperidines or spiropyrrolidines
  申请人：Hossain Nafizal

  公开号：US20050245741A1

  公开（公告）日：2005-11-03

  The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , t and R 9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）的化合物，其中m、R1、n、R2、q、X、Y、Z、R3、R4、R5、R6、R7、R8、t和R9如规范中所定义，以及它们的制备方法、包含它们的制药组合物及其在治疗中的应用。
• Novel Tricyclic Spiropiperidines or Spiropyrrolidines
  申请人：Hossain Nafizal

  公开号：US20090062322A1

  公开（公告）日：2009-03-05

  The invention provides compounds of formula (I) wherein m R 1 , n, R 2 , q, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , t, and R 9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明提供了式(I)的化合物，其中m，R1，n，R2，q，X，Y，Z，R3，R4，R5，R6，R7，R8，t和R9如规范中所定义，以及制备它们的过程，包含它们的制药组合物以及它们在治疗中的使用。
• Tricyclic spiropiperidines or spiropyrrolidines
  申请人：AstraZeneca AB

  公开号：US07449475B2

  公开（公告）日：2008-11-11

  The invention provides compounds of formula (I) wherein m R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t, and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式(I)的化合物，其中m，R1，n，R2，q，X，Y，Z，R3，R4，R5，R6，R7，R8，t和R9如规范中所定义，其制备过程，包含它们的制药组合物以及它们在治疗中的应用。
• Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists
  作者：Nafizal Hossain、Svetlana Ivanova、Jonas Bergare、Marguérite Mensonides-Harsema、Martin E. Cooper

  DOI：10.1016/j.bmcl.2013.04.047

  日期：2013.6

  A series of CCR1 antagonists based upon spirocyclic compounds 1b and 2b were synthesised in which substituted aniline moiety was replaced with substituted benzamides. In vitro data revealed that CCR1 potency could be retained in such compounds. (C) 2013 Elsevier Ltd. All rights reserved.